Article
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research - 2 Mar 2026
Blanc-Durand Félix, Genestie Catherine, Nikolaev Sergey, Leman Raphael, Church David N, Beinse Guillaume, Tredan Olivier, Bengrine Lefevre Leïla, Brachet Pierre-Emmanuel, Lebreton Coriolan, Meynard Guillaume, Fournel Pierre, Frenel Jean-Sébastien, Selle Frédéric, Cornila Corina, Fernandez Diez Yolanda, Bonnet Elise, Arnaud Antoine, Kaczmarek Emilie, Follana Philippe, Hardy-Bessard Anne-Claire, Fabbro Michel, Cojean Zelek Isabelle, Roche Sophie, Duliege Delphine, Mouret-Reynier Marie Ange, Bouchaert Patrick, Alexandre Jérôme, Joly Florence, Leary Alexandra
Abstract excerpt
PURPOSE: Aromatase inhibitors (AI) are used to treat estrogen receptor (ER)-positive low-grade endometrioid endometrial cancer. In breast cancer, ESR1 mutations are rare at diagnosis (<5%) but are frequently acquired in AI-resistant cases and are considered one of the major resistance mechanisms to endocrine therapy. This study aimed to assess the prevalence of ESR1 mutations in hormonotherapy-naïve endometrial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.